Pharmaceutical Services | Home Page

News

- 24/11/2022 EMA recommends approval of VidPrevtyn Beta as a COVID-19 booster vaccine

- 23/11/2022 EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders

- 02/11/2022 EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age

- 02/11/2022 EMA recommends approval of second adapted Spikevax vaccine

- 02/11/2022 EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders

- 21/09/2022 EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines

- 13/09/2022 Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval

- 09/09/2022 ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines

- 09/09/2022 COVID-19: recommendations on use of adapted vaccines

- 09/09/2022 Review of pholcodine medicines started